Ergoteles’s Immunic IMUX Stock Holding History

Ergoteles’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,401	Closed	-$19.6K	–	1481
2022 Q4	$19.6K	Sell	1,401 -1,072	-43%	-$29.2K	﹤0.01%	1346
2022 Q3	$78K	Sell	2,473 -6,567	-73%	-$275K	﹤0.01%	1408
2022 Q2	$314K	Buy	+9,040	New	+$579K	0.01%	1083

Other funds holding IMUX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Ergoteles's IMUX Position: Q1 2023 in Review

Ergoteles sold out of Immunic (IMUX) in Q1 2023, closing a stake of 1,401 shares — an estimated $19.6K sold.

Ergoteles first reported a position in IMUX in Q2 2022 and held it in 3 quarters. The position peaked at $314K in Q2 2022. 59 funds tracked by Wall St. Rank hold IMUX as of Q1 2023.

Ergoteles reported no remaining Immunic position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 1,401 Immunic shares in Q1 2023, an estimated $19.6K.
Ergoteles first reported a position in Immunic in Q2 2022 and held it in 3 quarters.
Ergoteles's Immunic position peaked at $314K in Q2 2022.
59 funds tracked by Wall St. Rank held Immunic as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.